blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2114372

EP2114372 - PHARMACEUTICAL CARRIER COMPOSITION AND PHARMACEUTICAL COMPOSITION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.03.2015
Database last updated on 14.09.2024
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): TR		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
Dafra Pharma N.V.
Slachthuisstraat 30/7
2300 Turnhout / BE
[2009/46]
Inventor(s)01 / JANSEN, Frans, Herwig
Witte Bremlaan 30
B-2360 Oud-Turnhout / BE
 [2009/46]
Representative(s)van Kooij, Adriaan, et al
Arnold & Siedsma
Bezuidenhoutseweg 57
2594 AC The Hague / NL
[N/P]
Former [2014/21]van Kooij, Adriaan, et al
Arnold & Siedsma
Sweelinckplein 1
2517 GK Den Haag / NL
Former [2009/46]van Kooij, Adriaan, et al
Arnold & Siedsma Sweelickplein 1
2517 GK Den Haag / NL
Application number, filing date08707701.213.02.2008
[2009/46]
WO2008EP01093
Priority number, dateWO2007EP0123413.02.2007         Original published format: PCT/EP2007/001234
[2009/46]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008098750
Date:21.08.2008
Language:EN
[2008/34]
Type: A1 Application with search report 
No.:EP2114372
Date:11.11.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 21.08.2008 takes the place of the publication of the European patent application.
[2009/46]
Type: B1 Patent specification 
No.:EP2114372
Date:21.05.2014
Language:EN
[2014/21]
Search report(s)International search report - published on:EP21.08.2008
ClassificationIPC:A61K9/10, A61K47/26, A61K47/38, A61K31/135, A61K31/335
[2009/46]
CPC:
A61K9/0095 (EP,US); A61K31/137 (EP,US); A61K31/335 (EP,US);
A61K31/47 (EP,US); A61K47/26 (EP,US); A61K47/38 (EP,US);
Y02A50/30 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/46]
TitleGerman:PHARMAZEUTISCHE TRÄGERZUSAMMENSETZUNG UND PHARMAZEUTISCHE ZUSAMMENSETZUNG[2009/46]
English:PHARMACEUTICAL CARRIER COMPOSITION AND PHARMACEUTICAL COMPOSITION[2009/46]
French:COMPOSITION D'EXCIPIENT PHARMACEUTIQUE ET COMPOSITION PHARMACEUTIQUE[2009/46]
Entry into regional phase25.08.2009National basic fee paid 
25.08.2009Designation fee(s) paid 
25.08.2009Examination fee paid 
Examination procedure25.08.2009Examination requested  [2009/46]
19.11.2009Despatch of a communication from the examining division (Time limit: M06)
18.05.2010Reply to a communication from the examining division
08.02.2012Despatch of a communication from the examining division (Time limit: M04)
25.05.2012Reply to a communication from the examining division
13.06.2012Despatch of a communication from the examining division (Time limit: M04)
04.10.2012Reply to a communication from the examining division
24.10.2013Cancellation of oral proceeding that was planned for 26.11.2013
20.11.2013Communication of intention to grant the patent
26.11.2013Date of oral proceedings (cancelled)
24.12.2013Fee for grant paid
24.12.2013Fee for publishing/printing paid
19.03.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  19.11.2009
Opposition(s)24.02.2015No opposition filed within time limit [2015/18]
Fees paidRenewal fee
26.02.2010Renewal fee patent year 03
28.04.2011Renewal fee patent year 04
28.02.2012Renewal fee patent year 05
25.02.2013Renewal fee patent year 06
25.02.2014Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
28.02.201104   M06   Fee paid on   28.04.2011
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.02.2008
BG21.05.2014
CY21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
IT21.05.2014
LT21.05.2014
LV21.05.2014
MC21.05.2014
MT21.05.2014
PL21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
AT13.02.2015
IE13.02.2015
LU13.02.2015
TR13.02.2015
[2024/42]
Former [2017/39]HU13.02.2008
BG21.05.2014
CY21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
IT21.05.2014
LT21.05.2014
LV21.05.2014
MC21.05.2014
MT21.05.2014
PL21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
AT13.02.2015
IE13.02.2015
LU13.02.2015
Former [2017/03]CZ21.05.2014
DK21.05.2014
EE21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
IT21.05.2014
LT21.05.2014
LV21.05.2014
MC21.05.2014
MT21.05.2014
PL21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
AT13.02.2015
IE13.02.2015
LU13.02.2015
Former [2016/32]CZ21.05.2014
DK21.05.2014
EE21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
IT21.05.2014
LT21.05.2014
LV21.05.2014
MC21.05.2014
PL21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
AT13.02.2015
IE13.02.2015
LU13.02.2015
Former [2016/25]BE21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
IT21.05.2014
LT21.05.2014
LV21.05.2014
MC21.05.2014
PL21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
AT13.02.2015
IE13.02.2015
LU13.02.2015
Former [2016/07]BE21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
IT21.05.2014
LT21.05.2014
LV21.05.2014
MC21.05.2014
PL21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
IE13.02.2015
LU13.02.2015
Former [2015/46]BE21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
IT21.05.2014
LT21.05.2014
LV21.05.2014
MC21.05.2014
PL21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
LU13.02.2015
Former [2015/44]BE21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
IT21.05.2014
LT21.05.2014
LV21.05.2014
PL21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
LU13.02.2015
Former [2015/36]BE21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
IT21.05.2014
LT21.05.2014
LV21.05.2014
PL21.05.2014
RO21.05.2014
SE21.05.2014
SI21.05.2014
SK21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
Former [2015/22]BE21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
IT21.05.2014
LT21.05.2014
LV21.05.2014
PL21.05.2014
RO21.05.2014
SE21.05.2014
SK21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
Former [2015/11]BE21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
LT21.05.2014
LV21.05.2014
PL21.05.2014
RO21.05.2014
SE21.05.2014
SK21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
Former [2015/10]BE21.05.2014
CZ21.05.2014
DK21.05.2014
EE21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
LT21.05.2014
LV21.05.2014
PL21.05.2014
SE21.05.2014
SK21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
Former [2015/08]BE21.05.2014
DK21.05.2014
ES21.05.2014
FI21.05.2014
HR21.05.2014
LT21.05.2014
LV21.05.2014
PL21.05.2014
SE21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
Former [2015/02]ES21.05.2014
FI21.05.2014
HR21.05.2014
LT21.05.2014
LV21.05.2014
PL21.05.2014
SE21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
PT22.09.2014
Former [2014/50]ES21.05.2014
FI21.05.2014
HR21.05.2014
LT21.05.2014
LV21.05.2014
PL21.05.2014
SE21.05.2014
NO21.08.2014
GR22.08.2014
IS21.09.2014
Former [2014/49]FI21.05.2014
LT21.05.2014
NO21.08.2014
IS21.09.2014
Former [2014/48]LT21.05.2014
Cited inInternational search[A]WO9202217  (CIBA GEIGY AG [CH], et al) [A] 1-19* the whole document *;
 [X]US6214386  (SANTUS GIANCARLO [IT], et al) [X] 1-19 * column 12; example 8 *;
 [X]WO02069939  (ORTHO MCNEIL PHARM INC [US]) [X] 1-19 * page 17; example 6 *;
 [X]US6515008  (TIONGSON ANTONIO S [US], et al) [X] 1-19 * column 5; example 1 *;
 [A]WO2004075817  (UNIV BRUXELLES [BE], et al) [A] 1-19 * the whole document *;
 [X]EP1652524  (SCHERING CORP [US]) [X] 1-19 * page 2, paragraph 2 - paragraph 3 * * page 9; example 10 *;
 [X]US2006198895  (KOTLIAR ELEONORA M [IL], et al) [X] 1-19 * page 1, paragraph 5 - paragraph 7 * * page 2, paragraph 22 * * page 3 - page 4; example 1 *
Examination   - M. GABRIELS; J. PLAIZIER-VERCAMMEN, "Experimental designed optimization and stability evaluation of dry suspensions with artemisinin derivatives for paediatric use", INTERNATIONAL JOURNAL OF PHARMACEUTICS, (20040823), vol. 283, doi:doi:10.1016/j.ijpharm.2004.05.033, ISSN 0378-5173, pages 19 - 34, XP004560628

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2004.05.033
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.